Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOLIZEM
- Development stage
- Phase 4
- Lead developer
- Ventrus Biosciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DOLIZEM (VEN 307) is a topical 2% diltiazem hydrochloride cream developed by Ventrus Biosciences for the treatment of pain associated with anal fissures. Diltiazem is a calcium-channel blocker that works by normalizing internal anal sphincter pressure and reducing maximal resting pressure. Its vasodilatory properties also improve local blood flow to the affected area, which aids in the healing process and alleviates pain. The drug was developed via the FDA's 505(b)(2) regulatory pathway, leveraging the established safety profile of oral diltiazem. Despite achieving statistical significance in its first Phase 3 clinical trial, a second Phase 3 trial failed to meet the primary endpoint due to a high placebo response, leading to the termination of the development program for this indication.
- Brand names
- DOLIZEM
- Other names
- Diltiazem Hydrochloride 2% Cream
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on DOLIZEM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOLIZEM.